Castle Biosciences (NasdaqGM:CSTL) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsCamilla Zuckero - Vice President, Investor Relations and Corporate AffairsCarlos Peniche - Former Equity Research AssociateDerek Maetzold - Founder, President, and CEOFrank Stokes - CFOThomas Heinzen - Managing Director in Healthcare Investment BankingConference Call ParticipantsAlex Vukasin - Healthcare Equity Research AnalystJosh R. Waldman - Equity Research AnalystMason Carrico - Research AnalystMat ...

Castle Biosciences (NasdaqGM:CSTL) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker6Good afternoon, and welcome to Castle Biosciences's fourth quarter and full year 2025 conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs.Speaker1Thank you, operator. Good afternoon, ...

站在2026年的起点，回望刚刚过去的2025年，生物技术与信息技术的融合终于迈过了临界点。 对于华大而言，这一年的核心变化在于我们如何利用人工智能技术，重新定义了基因检测的效率与边界。 长期以来，基因测序行业解决的主要问题是"读"，我们通过不断降低测序成本，把生命的ATCG序列准确地读取出来，但面对海量的数据，如何"懂"成为新 问题。 2025年，随着华大生命科学研究院发布全球首个百亿参数人类基因组通用基础模型Genos，以及华大基因推出多模态大模型GeneT，我们开始尝试解决这个 问题。 Genos基于全球不同人群的636个高质量基因组进行训练。 它的一项关键能力，是对基因组中非编码区域的解析。在过去，这部分区域因为难以解读，往往被忽视，但它们实际上决定了大量的生命调控机制，Genos 利用长上下文分析能力，能够在这片未知区域中以单碱基的精度进行识别和分析。 基于Genos的底层能力，我们推出了面向临床应用的GeneT，这是一个更贴近具体业务场景的工具。 在临床遗传咨询中，专业人员的短缺一直是制约行业发展的因素。GeneT通过连接知识库与测序数据，能够辅助生成专业的诊疗建议与报告，通过基础模型 加应用平台的 ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to a strategic adjustment in sales, leading to a temporary decrease in revenue [1] Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] Strategic Adjustments - The decline in revenue and net profit is attributed to the company's adjustment in sales strategy, which resulted in a temporary drop in revenue [1] - Fixed costs such as labor, rent, and depreciation contributed to the reduction in net profit despite the revenue decline [1] Market Presence - As of June 30, 2025, the company collaborates with healthcare institutions in over 340 cities across China, enabling it to provide genetic testing services to a large portion of the Chinese population [1] - The company has partnered with several e-commerce and online healthcare platforms to expand and enhance its sales and marketing network [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to adjustments in sales strategy and fixed costs impacting profitability [1] Financial Performance - The company achieved operating revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] - Earnings per share attributable to ordinary equity holders of the parent company was RMB 0.13 [1] Business Operations - The company is a leading gene testing platform in China, focusing on consumer-grade gene testing services and cancer screening [1] - As of June 30, 2025, the company has conducted over 24 million gene tests [1] - The company collaborates with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network to provide gene testing services to a large portion of the population [1] - Partnerships with various e-commerce and online healthcare platforms are in place to expand and improve the sales and marketing network [1]

Market Overview - The A-share market showed mixed performance today, with the Shanghai Composite Index rising by 0.27% to close at 4151.24 points, while the Shenzhen Component Index increased by 0.09% to 14342.89 points. However, the ChiNext Index fell by 0.57% to 3323.56 points, and the STAR 50 Index decreased by 0.08% to 1554.8 points. Overall, there were 1736 stocks that rose and 3636 stocks that fell, with a total trading volume of 29,654 billion yuan, an increase of 704 billion yuan compared to the previous trading day [1]. Industry Performance - Among the Shenwan first-level industries, sectors such as non-ferrous metals, petroleum and petrochemicals, coal, building materials, and steel led the gains, with increases of 5.92%, 3.54%, 3.42%, 2.18%, and 2.16% respectively. Conversely, industries such as comprehensive, media, national defense and military industry, beauty care, and pharmaceutical biology experienced declines, with decreases of 2.53%, 1.77%, 1.68%, 1.65%, and 1.56% respectively [1]. Concept Sector Performance - The concept sectors that performed well today included gold and jewelry, selected industrial metals, fiberglass, nickel ore, small metals, selected rare metals, copper industry, cobalt ore, selected coal mining, advanced packaging, germanium-gallium-antimony ink, central enterprise coal, aluminum industry, selected chemical raw materials, and oil and gas extraction. In contrast, sectors such as genetic testing, selected medical devices, industrial mother machines, and selected power equipment saw a pullback [2].

Group 1 - Recent cases of Nipah virus infection have been reported in West Bengal, India, prompting countries like Thailand and Nepal to enhance preventive measures at airports and border checkpoints [1] - The World Health Organization recognizes Nipah virus as a significant global public health challenge due to its long incubation period, ability to infect various animals and humans, and high fatality rate [1] - Several Chinese gene testing companies have quickly responded to the outbreak by developing testing solutions, showcasing their technological capabilities and emergency response abilities [1] Group 2 - Guangzhou Kingmed Diagnostics Group Co., Ltd. has developed a MetaVirus NGS detection service for precise detection and analysis of Nipah virus and other pathogens, providing reports within 19 hours from sample entry [2] - Beijing Bohui Innovation Biotechnology Group has created a Nipah virus nucleic acid testing kit, utilizing the BHQ-Ⅲ automated nucleic acid analysis system to ensure safety and reduce operational risks [2] - Capbio has independently developed a Nipah virus nucleic acid testing kit, focusing on emergency responses to public health events and providing core technical support for global quarantine and disease control monitoring [1][2]

Core Viewpoint - Antu Biology (603658) has launched the Si kun series of gene sequencers, marking a significant milestone in its path of independent innovation and providing a high-cost performance, open-compatible, and self-controlled domestic option in the gene detection market [3]. Group 1: Product Launch - The Si kun series includes three models: Si kun 2000, Si kun 1000, and Si kun 500, designed to meet the differentiated throughput needs of various medical institutions [3]. - The sequencers are applicable in clinical scenarios such as tumor gene testing, genetic disease screening, and pathogen monitoring [3]. - Key optical systems, biochemical enzyme materials, base reagents, and core algorithms related to the sequencers have been fully self-developed, eliminating reliance on imported supply chains [3]. Group 2: Market Impact - The launch of the Si kun series fills a product gap for Antu Biology in the gene detection field [3]. - The new products represent a substantial breakthrough in constructing a comprehensive gene detection solution that includes instruments, reagents, and software [3].

Core Viewpoint - Antu Biology has achieved a significant breakthrough in gene detection with the approval of its Sikun series gene sequencers, marking a strategic shift from traditional biochemical detection to precision diagnostics [1][3]. Company Developments - Antu Biology's Sikun series gene sequencers (Sikun2000, Sikun1000, Sikun500) received medical device registration certificates from the National Medical Products Administration, allowing them to enter the clinical testing market, with an expected launch in January 2026 [1]. - The company emphasizes that this is its first sequencing instrument registration certificate, which is strategically important for its development [1]. - The Sikun series is fully self-developed and utilizes reversible terminator technology, facilitating a smooth transition for medical institutions while ensuring data quality and reducing labor and time costs [1]. Industry Insights - The gene testing market in China has shown continuous growth, with the market size increasing from 7.2 billion yuan in 2016 to an expected 37.4 billion yuan by 2024, and projected to reach 153.6 billion yuan by 2030, reflecting a compound annual growth rate of 25.8% over the next five years [2]. - The introduction of Antu Biology's three new products increases the total number of gene sequencers in the domestic market to ten, contributing to the upgrade of the domestic sequencing industry and accelerating the process of domestic substitution [2]. - The core components of the three products are entirely self-developed, moving away from the OEM model, which stabilizes the supply chain and enhances cost-effectiveness, while also driving the upgrade of upstream and downstream industries [3].

Core Insights - The article highlights a significant breakthrough in the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, with the approval of a targeted drug, Tofersen injection, in China, marking a new era of "etiological treatment" for the disease [3][8]. Group 1: Disease Overview and Patient Experience - ALS is a progressive neurodegenerative disease characterized by the gradual death of motor neurons in the brain and spinal cord, leading to muscle weakness and atrophy, with a typical survival period of 3 to 5 years [4][6]. - The article features the experience of a patient, Ms. Wenli, who has shown significant improvement in her condition after receiving the new targeted therapy, indicating a shift towards more effective treatment options [1][3]. Group 2: Advances in Genetic Testing - Genetic testing has become a crucial element in the precise diagnosis and treatment of ALS, with the identification of mutations such as SOD1 being pivotal for determining treatment eligibility [7][6]. - The detection rate of genetic mutations in sporadic ALS patients has improved significantly, reaching approximately 40%-50%, which is a notable increase compared to earlier averages [7][6]. Group 3: Treatment Innovations - The newly approved Tofersen injection targets the underlying cause of ALS by inhibiting the synthesis of the toxic SOD1 protein, thereby potentially delaying or preventing neuronal damage [8][11]. - The article shares success stories of patients who have experienced remarkable functional improvements after receiving the new treatment, showcasing the transformative potential of this therapy [8][11]. Group 4: Comprehensive Care and Support Systems - Effective ALS treatment requires a multidisciplinary approach, involving various medical specialties to ensure comprehensive patient care, from diagnosis to rehabilitation [13]. - The financial burden of innovative treatments, such as Tofersen, is being alleviated through charitable assistance and inclusion in local health insurance plans, making the drug more accessible to patients [14][16]. Group 5: Future Directions and Advocacy - There is a call for increased public awareness of ALS, the promotion of genetic testing, and the enhancement of healthcare networks to support patients in their fight against the disease [16].